Search

Your search keyword '"Lievre M."' showing total 177 results
Start Over Author "Lievre M."
177 results on '"Lievre M."'

1. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Author

Agodoa, L, Algra, A, Asselbergs, F W, Beckett, N, Berge, E, Black, H, Brouwers, F P J, Brown, M, Bulpitt, C J, Byington, B, Cutler, J, Devereaux, R B, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S E, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L H, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, M H, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Poulter, N R, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J A, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W H, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z Y, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J, Nazarzadeh, Milad, Bidel, Zeinab, Canoy, Dexter, Copland, Emma, Bennett, Derrick A, Dehghan, Abbas, Davey Smith, George, Holman, Rury R, Woodward, Mark, Gupta, Ajay, Adler, Amanda I, Wamil, Malgorzata, Sattar, Naveed, Cushman, William C, McManus, Richard J, Teo, Koon, Davis, Barry R, Chalmers, John, Pepine, Carl J, and Rahimi, Kazem

Published
2022
Full Text
View/download PDF

2. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Author

Adler, A, Agodoa, L, Algra, A, Asselbergs, F W, Beckett, N, Berge, E, Black, H, Brouwers, F P J, Brown, M, Bulpitt, C J, Byington, B, Chalmers, J, Cushman, W C, Cutler, J, Davis, B R, Devereaux, R B, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A K, Holman, R R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S E, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L H, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, M H, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C J, Pfeffer, M, Poulter, N R, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J A, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W H, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z Y, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J, Copland, Emma, Canoy, Dexter, Nazarzadeh, Milad, Bidel, Zeinab, Ramakrishnan, Rema, Woodward, Mark, Chalmers, John, Teo, Koon K, Pepine, Carl J, Davis, Barry R, Kjeldsen, Sverre, Sundström, Johan, and Rahimi, Kazem

Published
2021
Full Text
View/download PDF

4. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Author

Nazarzadeh, Milad, primary, Bidel, Zeinab, additional, Canoy, Dexter, additional, Copland, Emma, additional, Bennett, Derrick A, additional, Dehghan, Abbas, additional, Davey Smith, George, additional, Holman, Rury R, additional, Woodward, Mark, additional, Gupta, Ajay, additional, Adler, Amanda I, additional, Wamil, Malgorzata, additional, Sattar, Naveed, additional, Cushman, William C, additional, McManus, Richard J, additional, Teo, Koon, additional, Davis, Barry R, additional, Chalmers, John, additional, Pepine, Carl J, additional, Rahimi, Kazem, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Cutler, J, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional

Published
2022
Full Text
View/download PDF

5. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Author

Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., Teo K. K., Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., and Teo K. K.

Abstract

Background: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. Methods: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission. Findings: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59–75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55–64 years, 128 506 (35·8%) 65–74 years, 54 016 (15·1%) 75–84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg

Published
2021

6. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Author

Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., and Wang J.

Abstract

Background: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure. Methods: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat. Findings: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/8

Published
2021

9. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Author

Copland, Emma, primary, Canoy, Dexter, additional, Nazarzadeh, Milad, additional, Bidel, Zeinab, additional, Ramakrishnan, Rema, additional, Woodward, Mark, additional, Chalmers, John, additional, Teo, Koon K, additional, Pepine, Carl J, additional, Davis, Barry R, additional, Kjeldsen, Sverre, additional, Sundström, Johan, additional, Rahimi, Kazem, additional, Adler, A, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Chalmers, J, additional, Cushman, W C, additional, Cutler, J, additional, Davis, B R, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Gupta, A K, additional, Holman, R R, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pepine, C J, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Woodward, M, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional

Published
2021
Full Text
View/download PDF

11. Méthodologie d’évaluation et de mesure du progrès thérapeutique

Author

Alexandre, J.-M., Amede-Manesme, O., Bader, J.-P., Bouhassira, M., Calles, B., Castaigne, A., Chauvenet, M., Diquet, B., Giri, I., Ichou, F., Jolliet, P., Joubert, J.-M., Lehner, J.-P., Lièvre, M., Mathiex-Fortunet, H., Marty, M., Meyer, F., Micallef, J., Pigeon, M., Rouveix, B., Zannad, F., Guillemot, Didier, France, Georges, and Fender, Pierre

Published
2005
Full Text
View/download PDF

12. Methodology for the Evaluation and Measurement of Therapeutic Progress

Author

Alexandre, J.-M., Amede-Manesme, O., Bader, J.-P., Bouhassira, M., Calles, B., Castaigne, A., Chauvenet, M., Diquet, B., Giri, I., Ichou, F., Jolliet, P., Joubert, J.-M., Lehner, J.-P., Lièvre, M., Mathiex-Fortunet, H., Marty, M., Meyer, F., Micallef, J., Pigeon, M., Rouveix, B., Zannad, F., Guillemot, Didier, France, Georges, and Fender, Pierre

Published
2005
Full Text
View/download PDF

19. Subjective Outcome Measures of Drug Efficacy

Author

Arnould, B., Avouac, B., Chassany, O., Hamelin, B., Lapeyre, G., Lendresse, P., Leplège, A., Lièvre, M., Mathiex-Fortunet, H., Paintaud, G., Pigeon, M., Puech, A., Samoyeau, R., Spriet, A., Steinberg, G., Vilain, C., Courcier-Duplantier, Soizic, Falissard, Bruno, and Fender, Pierre

Published
2003
Full Text
View/download PDF

22. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials

Author

Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., Woodward M., Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., and Woodward M.

Abstract

Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (<25 kg/m2, 25 to <30 kg/m2, and ≥30 kg/m2) or a continuous variable. Findings Analyses were based on 135 715 individuals from 22 trials who had 14 353 major cardiovascular events. None of the six primary comparisons showed evidence that protection varied by drug class across the three BMI groups (all p for trend >0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.

Published
2015

23. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

Author

Rahimi, K, Canoy, D, Nazarzadeh, M, Salimi-Khorshidi, G, Woodward, M, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, N, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, B, Cutler, J, Devereaux, RB, Dwyer, D, Fagard, R, Fox, K, Fukui, T, Gupta, AJ, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Othisgihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Poulter, NR, Rakugi, H, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, Van Gilst, WH, Verdecchia, P, Wachtell, K, Yui, Y, Yusuf, S, Baigent, C, Collins, R, De Zeeuw, D, Neal, B, Perkovic, V, Rahman, M, Remme, WJ, Rodgers, A, Sundstrom, J, Turnbull, F, Foundation for Circulatory Health, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Staessen, Jan

Subjects
medicine.medical_specialty, Epidemiology, Disease, REGIMENS, 030204 cardiovascular system & hematology, Research Support, Phase (combat), 03 medical and health sciences, Medicine, General & Internal, 0302 clinical medicine, General & Internal Medicine, Diabetes mellitus, Protocol, medicine, Journal Article, Humans, 030212 general & internal medicine, Intensive care medicine, Non-U.S. Gov't, Stroke, Antihypertensive Agents, Randomized Controlled Trials as Topic, RISK, Protocol (science), Medicine(all), Science & Technology, efficacy and safety of bp lowering treatment, HYPERTENSION, business.industry, Research Support, Non-U.S. Gov't, blood pressure, General Medicine, medicine.disease, PROSPECTIVELY-DESIGNED OVERVIEWS, MODEL, Treatment Outcome, MAJOR CARDIOVASCULAR EVENTS, Blood pressure, Patient level data, meta-analyses, Blood pressure lowering, business, Life Sciences & Biomedicine, Blood Pressure Lowering Treatment Trialists’ Collaboration
Abstract

IntroductionPrevious research from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) and others has shown that pharmacological blood pressure (BP)- lowering substantially reduces the risk of major cardiovascular events, including ischaemic heart disease, heart failure and stroke. In this new phase, the aim is to conduct individual patient-level data (IPD) meta-analyses involving eligible BP-lowering randomised controlled trials (RCTs) to address uncertainties relating to efficacy and safety of BP-lowering treatment.Methods and analysisRCTs investigating the effect of pharmacological BP-lowering, with a minimum of 1000 patient-years of follow-up in each trial arm, are eligible. Our systematic review identified 100 potentially eligible trials. We requested their investigators/sponsors to contribute baseline, follow-up and outcomes data. As of June 2018, the collaboration has obtained data from 49 trials (n=315 046 participants), with additional data currently in the process of being transferred from four RCTs (n=34 642 participants). In addition, data harmonisation has commenced. Scientific activities of the collaboration are overseen by the Steering Committee with input from all collaborators. Detailed protocols for individual meta-analyses will be developed and registered on public platforms.Ethics and disseminationEthics approval has been obtained for this new and extended phase of the BPLTTC, the largest collaboration of de-identified IPD from RCTs. It offers an efficient and ethical manner of re-purposing existing data to answer clinically important questions relating to BP treatment as well as methodological questions relating to IPD meta-analyses. Among the immediate impacts will include reliable quantification of effects of treatment modifiers, such as baseline BP, age and prior disease, on both vascular and non-vascular outcomes. Analyses will further assess the impact of BP-lowering on important, but less well understood, outcomes, such as new-onset diabetes and renal disease. Findings will be published in peer-reviewed medical journals on behalf of the collaboration.

Published
2019

24. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

Author

Agodoa, L, Anderson, C, Asselbergs, FW, Baigent, C, Black, H, Brenner, B, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, de Zeeuw, D, Dens, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Hansson, L, Holman, R, Hunsicker, L, Imai, Y, Ishii, M, Kanno, Y, Kostis, J, Kuramoto, K, Lewis, E, Lievre, M, Lindholm, LH, Liu, L, Lubsen, J, Lueders, S, MacMahon, S, Malacco, E, Mancia, G, Matsuzaki, M, Neal, B, Nissen, S, Ohkubo, T, Ogihara, T, Pepine, C, Pfeffer, M, Pitt, B, Poole-Wilson, P, Poulter, N, Rahman, M, Remme, W, Remuzzi, G, Rodgers, A, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Teo, K, van Gilst, WH, Viberti, G, Wang, J, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Barzi, F, Heritier, S, Li, N, Ninomiya, T, Perkovic, V, Turnbull, F, Woodward, M, Wilson, K, Kearney, ACP, Gallagher, M, Cass, A, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Cardiology, Clinical Research Unit, Pathology, Graduate School, ACS - Heart failure & arrhythmias, and Amsterdam Reproduction & Development (AR&D)

Subjects
medicine.medical_specialty, Hemodynamics, Renal function, CONVERTING ENZYME-INHIBITOR, PLACEBO-CONTROLLED TRIAL, CALCIUM-ANTAGONIST, DOUBLE-BLIND, HYPERTENSIVE PATIENTS, RISK-FACTOR, Internal medicine, medicine, Myocardial infarction, Intensive care medicine, PUBLICATION BIAS, biology, business.industry, Research, Angiotensin-converting enzyme, General Medicine, medicine.disease, RENAL OUTCOMES, Blood pressure, ATHEROSCLEROSIS, Heart failure, Cardiology, Aortic pressure, biology.protein, CORONARY-ARTERY-DISEASE, business, Kidney disease
Abstract

Objective To define the cardiovascular effects of lowering blood pressure in people with chronic kidney disease.Design Collaborative prospective meta-analysis of randomised trials.Data sources and eligibility Participating randomised trials of drugs to lower blood pressure compared with placebo or each other or that compare different blood pressure targets, with at least 1000 patient years of follow-up per arm.Main outcome measures Major cardiovascular events (stroke, myocardial infarction, heart failure, or cardiovascular death) in composite and individually and all cause death.Participants 26 trials (152 290 participants), including 30 295 individuals with reduced estimated glomerular filtration rate (eGFR), which was defined as eGFRData extraction Individual participant data were available for 23 trials, with summary data from another three. Meta-analysis according to baseline kidney function was performed. Pooled hazard ratios per 5 mm Hg lower blood pressure were estimated with a random effects model.Results Compared with placebo, blood pressure lowering regimens reduced the risk of major cardiovascular events by about a sixth per 5 mm Hg reduction in systolic blood pressure in individuals with (hazard ratio 0.83, 95% confidence interval 0.76 to 0.90) and without reduced eGFR (0.83, 0.79 to 0.88), with no evidence for any difference in effect (P=1.00 for homogeneity). The results were similar irrespective of whether blood pressure was reduced by regimens based on angiotensin converting enzyme inhibitors, calcium antagonists, or diuretics/beta blockers. There was no evidence that the effects of different drug classes on major cardiovascular events varied between patients with different eGFR (all P>0.60 for homogeneity).Conclusions Blood pressure lowering is an effective strategy for preventing cardiovascular events among people with moderately reduced eGFR. There is little evidence from these overviews to support the preferential choice of particular drug classes for the prevention of cardiovascular events in chronic kidney disease.

Published
2016

25. Study of Thioridazine Cardiotoxic Effects by Means of His Bundle Activity Recording***

Author

Lievre M, Jacques Descotes, Ollagnier M, G. Fawon, and J. Ci. Evreux

Subjects
Pharmacology, Bundle of His, Thioridazine, business.industry, Chloralose, Refractory period, Effective refractory period, Toxicology, Clinical Practice, chemistry.chemical_compound, Dogs, chemistry, Thioridazine Hydrochloride, Heart Conduction System, Heart Rate, Anesthesia, Heart rate, Animals, Medicine, business, Intravenous route, medicine.drug
Abstract

The effect of thioridazine on sinusal automaticity, myocardial excitability and auriculoventricular conduction have been studied in dogs by measuring the spontaneous heart rate, the effective refractory period of the atrial contractile tissue, the time of auriculonodal and infrahisian conduction. Chloralose anaesthetized dogs were administered 10 mg/kg thioridazine hydrochloride via intravenous route. While sinusal automaticity was not altered, conduction times were prolonged in the suprahisian and mainly the infrahisian part and the atrial refractory period increased. These effects are related to quinidine-like properties and consistent with cardiotoxic effects previously reported in clinical practice.

Published
2009

26. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index : A meta-analysis of randomised trials

Author

Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Epidemiology and Data Science, Graduate School, APH - Methodology, and APH - Personalized Medicine

Subjects
medicine.medical_specialty, DISEASE, Body Mass Index, EVENTS, Internal medicine, medicine, Humans, Obesity, Stroke, Antihypertensive Agents, METABOLIC SYNDROME, Randomized Controlled Trials as Topic, Medicine(all), business.industry, MORTALITY, Hazard ratio, General Medicine, medicine.disease, PREVENTION, EUROPEAN-SOCIETY, PROSPECTIVELY-DESIGNED OVERVIEWS, REDUCTION, Blood pressure, Cardiovascular Diseases, Heart failure, Meta-analysis, Hypertension, Physical therapy, Metabolic syndrome, business, Body mass index, Risk Reduction Behavior
Abstract

Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.

Published
2015

27. Management of adolescents with very poorly controlled type 1 diabetes by nurses: a parallel group randomized controlled trial

Author

Kassai, B., Rabilloud, Muriel, Bernoux, D., Michal, C., Riche, B., Ginhoux, T., Laudy, V., Terral, D., Didier-Wright, C., Maire, V., Dumont, C., Cottancin, G., Plasse, M., Jeannoel, G. P., Khoury, J., Bony, C., Lievre, M., Drai, Jocelyne, Nicolino, Marc, Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Blood Glucose, Counseling, Male, Health Knowledge, Attitudes, Practice, Time Factors, Adolescent, [SDV]Life Sciences [q-bio], Health Behavior, Medicine (miscellaneous), Diabetes mellitus, Surveys and Questionnaires, Adaptation, Psychological, Humans, Pharmacology (medical), Child, Glycated Hemoglobin, Research, Self Care, Diabetes Mellitus, Type 1, Treatment Outcome, Randomized controlled trial, Adolescent Behavior, Patient Satisfaction, Female, France, Biomarkers, Type 1
Abstract

International audience; BACKGROUNDS: Fluctuation in glycemia due to hormonal changes, growth periods, physical activity, and emotions make diabetes management difficult during adolescence. Our objective was to show that a close control of patients' self-management of diabetes by nurse-counseling could probably improve metabolic control in adolescents with type 1 diabetes. METHODS: We designed a multicenter, randomized controlled, parallel group, clinical trial. Seventy seven adolescents aged 12-17 years with A1C \textgreater8% were assigned to either an intervention group (pediatrician visit every 3 months + nurse visit and phone calls) or to the control group (pediatrician visit every 3 months). The primary outcome was the evolution of the rate of A1C during the 12 months of follow-up. Secondary outcomes include patient's acceptance of the disease (evaluated by visual analog scale), the number of hypoglycemic or ketoacidosis episodes requiring hospitalization, and evaluation of A1C rate over time in each group. RESULTS: Seventy-seven patients were enrolled by 10 clinical centers. Seventy (89.6%) completed the study, the evolution of A1C and participants satisfaction over the follow-up period was not significantly influenced by the nurse intervention. CONCLUSION: Nurse-led intervention to improve A1C did not show a significant benefit in adolescents with type 1 diabetes because of lack of power. Only psychological management and continuous glucose monitoring have shown, so far, a slight but significant benefit on A1C. We did not show improvements in A1C control in teenagers by nurse-led intervention. TRIAL REGISTRATION: Clinical Trials.gov registration number: NCT00308256, 28 March 2006.

Published
2015

28. Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry

Author

Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., Massetti M. (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., and Massetti M. (ORCID:0000-0002-7100-8478)

Abstract

Background Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. Objectives This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. Methods The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. Results A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p < 0.001), low body mass index, (p < 0.001), atrial fibrillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p < 0.001), higher logistic EuroSCORE (p < 0.001), transapical or subclavian approach (p < 0.001 for both vs. transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant periprosthetic aortic regurgitation grade ≥2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in <2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. Conclusions The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac

Published
2016

29. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials

Author

Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., and Woodward, M.

Published
2015

30. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system

Author

Agodoa, L, Anderson, C, Asseibergs, F, Baigent, C, Black, H, Brenner, B, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, de Zeeuw, D, Dens, J, Estacio, R, Fagard, Robert, Fox, K, Fukui, T, Hansson, L, Holman, R, Hunsicker, L, Imai, Y, Ishii, M, Kanno, Y, Kostis, J, Kuramoto, K, Lewis, E, Lievre, M, Lindholm, LH, Liu-Huang, Li-chuan, Lubsen, J, Lueders, S, MacMahon, S, Malacco, E, Mancia, G, Matsuzaki, M, Neal, B, Nissen, S, Ohkubo, T, Ogihara, T, Pepine, C, Pfeffer, M, Pitt, B, Poole-Wilson, P, Rahman, M, Remme, W, Remuzzi, G, Rodgers, A, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, Jan A, Teo, K, Viberti, G, Wang, J, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Swedberg, K, Kjekshus, J, Algert, C, Perkovic, V, Turnbull, F, Woodward, M, and Groningen Kidney Center (GKC)

Subjects
coronary-artery-disease, Physiology, CONVERTING-ENZYME-INHIBITORS, converting-enzyme-inhibitors, Placebo-controlled study, heart failure, Angiotensin-Converting Enzyme Inhibitors, high-risk patients, 030204 cardiovascular system & hematology, PLACEBO-CONTROLLED TRIAL, Renin-Angiotensin System, Coronary artery disease, 0302 clinical medicine, placebo-controlled trial, HYPERTENSIVE PATIENTS, 030212 general & internal medicine, prospectively-designed overviews, Stroke, Randomized Controlled Trials as Topic, major cardiovascular events, blood pressure, stroke, CHRONIC HEART-FAILURE, 3. Good health, Cardiovascular Diseases, randomized controlled-trial, Cardiology, ventricular systolic function, Cardiology and Cardiovascular Medicine, meta-regression analyses, RECEPTOR BLOCKERS, medicine.medical_specialty, Placebo, Sensitivity and Specificity, 03 medical and health sciences, VENTRICULAR SYSTOLIC FUNCTION, Internal medicine, Renin–angiotensin system, Internal Medicine, medicine, Humans, CARDIOVASCULAR MORBIDITY, cardiovascular diseases, coronary heart disease, HIGH-RISK PATIENTS, lipid-lowering treatment, business.industry, medicine.disease, RANDOMIZED-TRIAL, chronic heart-failure, Blood pressure, MYOCARDIAL-INFARCTION, meta-analyses, Relative risk, Heart failure, business, Angiotensin II Type 1 Receptor Blockers
Abstract

Objectives To evaluate the blood pressure-dependent and independent effects of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on major cardiovascular events.Methods Using data from 26 large-scale trials comparing an ACEI or an ARB with placebo or another drug class, meta-regression analyses were conducted in which treatment-specific relative risks for major cause-specific outcomes [stroke, major coronary heart disease (CHD) events and heart failure] were regressed against follow-up blood pressure differences.Results From a total of 146 838 individuals with high blood pressure or an elevated risk of cardiovascular disease, 22 666 major cardiovascular events were documented during follow-up. The analyses showed comparable blood pressure-dependent reductions in risk with ACEI and ARB (P > 0.3 for all three outcomes). The analyses also showed that ACEI produced a blood pressure-independent reduction in the relative risk of CHD of approximately 9% (95% confidence interval 3-14%). No similar effect was detected for ARB, and there was some evidence of a difference between ACEI and ARB in this regard (P =0.002). For both stroke and heart failure there was no evidence of any blood pressure-independent effects of either ACEI or ARB.Conclusion There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure. For ACEI, but not ARB, there is evidence of blood pressure-independent effects on the risk of major coronary disease events.

Published
2007

31. Type 2 diabetes and cardiovascular risk: Lessons from therapeutic trials

Author

Lievre, M., Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]
Published
2004

35. Registry of transcatheter aortic-valve implantation in high-risk patients

Author

Gilard, M., Eltchaninoff, H., Iung, B., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Himbert, D., Tchetche, D., Carriè, D., Albat, B., Cribier, A., Rioufol, G., Sudre, A., Blanchard, D., Collet, F., Dos Santos, P., Meneveau, N., Tirouvanziam, A., Caussin, C., Guyon, P., Boschat, J., Le Breton, H., Collart, F., Houel, R., Delpine, S., Souteyrand, G., Favereau, X., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Massetti, Massimo, Massetti, Massimo (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Iung, B., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Himbert, D., Tchetche, D., Carriè, D., Albat, B., Cribier, A., Rioufol, G., Sudre, A., Blanchard, D., Collet, F., Dos Santos, P., Meneveau, N., Tirouvanziam, A., Caussin, C., Guyon, P., Boschat, J., Le Breton, H., Collart, F., Houel, R., Delpine, S., Souteyrand, G., Favereau, X., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Massetti, Massimo, and Massetti, Massimo (ORCID:0000-0002-7100-8478)

Abstract

Transcatheter aortic-valve implantation (TAVI) is an emerging intervention for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses. We report the results of a prospective multicenter study of the French national transcatheter aortic-valve implantation registry, FRANCE 2.

Published
2012

46. Efectos cardiovasculares y renales de dosis bajas de ramipril en pacientes diabéticos tipo 2 con excreción urinaria de albúmina elevada: estudio aleatorizado, doble ciego, controlado con placebo (Estudio DIABHYCAR)

Author

Marre, M., primary, Lievre, M., additional, Chatellier, G., additional, Mann, J.F., additional, Passa, P., additional, Ménard, J., additional, Bonet, A., additional, Flores, I., additional, Egocheaga, M.I., additional, Domínguez, M., additional, Nevado, A., additional, Iglesias, J.M., additional, Dalfó, A., additional, Pepió, J.M., additional, Ureña, T., additional, Sanchís, C., additional, and Paja, E., additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results